Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer Hospital.
Fujiwara Y, Sato Y, Wang X, Oikado K, Sato Y, Fukuda N, Enokida T, Takeda K, Ohkushi D, Hayama B, Egi Y, Tokai Y, Yamada Y, Nakajima Y, Kubota M, Haruki S, Shimizu T, Uchida Y, Utsugi K, Ito Y, Ohno S, Takahashi S, Tsuchida T; COVID-19 Working Group of The Cancer Institute Hospital of Japanese Foundation for Cancer Research. Fujiwara Y, et al. Among authors: fukuda n. Cancer Cell. 2020 Nov 9;38(5):609-610. doi: 10.1016/j.ccell.2020.09.017. Epub 2020 Oct 2. Cancer Cell. 2020. PMID: 33064994 Free PMC article. No abstract available.
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.
Fukuda N, Fujiwara Y, Wang X, Ohmoto A, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Takahashi S. Fukuda N, et al. Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3037-3043. doi: 10.1007/s00405-020-06481-y. Epub 2020 Nov 21. Eur Arch Otorhinolaryngol. 2021. PMID: 33219858
Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line.
Nakano K, Hayakawa K, Funauchi Y, Tanizawa T, Ae K, Matsumoto S, Tomomatsu J, Ono M, Taira S, Nishizawa M, Wang X, Ohmoto A, Sato Y, Fukuda N, Urasaki T, Takahashi S. Nakano K, et al. Among authors: fukuda n. Mol Clin Oncol. 2021 Jan;14(1):13. doi: 10.3892/mco.2020.2175. Epub 2020 Nov 25. Mol Clin Oncol. 2021. PMID: 33282288 Free PMC article.
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Fukuda N, Yunokawa M, Fujiwara Y, Wang X, Ohmoto A, Hayashi N, Urasaki T, Sato Y, Nakano K, Ono M, Tomomatsu J, Mitani H, Takahashi S. Fukuda N, et al. Cancer Rep (Hoboken). 2021 Apr;4(2):e1322. doi: 10.1002/cnr2.1322. Epub 2020 Dec 9. Cancer Rep (Hoboken). 2021. PMID: 33295110 Free PMC article.
1,216 results